Article
Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.
Thoracic cancer - 1 Sept 2018
Kang Jin, Chen Hua-Jun, Zhang Xu-Chao, Su Jian, Zhou Qing, Tu Hai-Yan, Wang Zhen, Wang Bin-Chao, Zhong Wen-Zhao, Yang Xue-Ning, Chen Zhi-Hong, Ding Yan, Wu Xue, Wang Mei, Fu Jian-Gang, Yang Zhenfan, Zhang Xian, Shao Yang W, Wu Yi-Long, Yang Jin-Ji
Abstract excerpt
BACKGROUND: ALK-tyrosine kinase inhibitors (TKIs) have been proven effective for treating ALK-positive non-small cell lung cancer (NSCLC), although patients present with variable responses and disease progression courses. The detailed underlying molecular mechanisms require further investigation to yield a better prognosis. METHODS: Targeted next-generation sequencing (NGS) mutation profiling was performed on...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.